Spero Therapeutics Statistics
Total Valuation
SPRO has a market cap or net worth of $52.49 million. The enterprise value is -$55.44 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SPRO has 58.23 million shares outstanding. The number of shares has increased by 3.53% in one year.
| Current Share Class | 58.23M |
| Shares Outstanding | 58.23M |
| Shares Change (YoY) | +3.53% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 3.27% |
| Owned by Institutions (%) | 28.75% |
| Float | 47.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.25 |
| Forward PS | n/a |
| PB Ratio | 70.56 |
| P/TBV Ratio | 66.50 |
| P/FCF Ratio | 2.65 |
| P/OCF Ratio | 2.65 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -216.41% and return on invested capital (ROIC) is 32.09%.
| Return on Equity (ROE) | -216.41% |
| Return on Assets (ROA) | 5.35% |
| Return on Invested Capital (ROIC) | 32.09% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 12.85% |
| Revenue Per Employee | $1.66M |
| Profits Per Employee | -$1.18M |
| Employee Count | 25 |
| Asset Turnover | 0.51 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SPRO has paid $261,000 in taxes.
| Income Tax | 261,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.60% in the last 52 weeks. The beta is 1.56, so SPRO's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | -62.60% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 1.90 |
| Relative Strength Index (RSI) | 31.59 |
| Average Volume (20 Days) | 338,165 |
Short Selling Information
The latest short interest is 787,025, so 1.35% of the outstanding shares have been sold short.
| Short Interest | 787,025 |
| Short Previous Month | 840,529 |
| Short % of Shares Out | 1.35% |
| Short % of Float | 1.67% |
| Short Ratio (days to cover) | 1.69 |
Income Statement
In the last 12 months, SPRO had revenue of $41.56 million and -$29.51 million in losses. Loss per share was -$0.51.
| Revenue | 41.56M |
| Gross Profit | 3.09M |
| Operating Income | 7.03M |
| Pretax Income | -29.25M |
| Net Income | -29.51M |
| EBITDA | n/a |
| EBIT | 7.03M |
| Loss Per Share | -$0.51 |
Full Income Statement Balance Sheet
The company has $107.93 million in cash and no debt, with a net cash position of $107.93 million or $1.85 per share.
| Cash & Cash Equivalents | 107.93M |
| Total Debt | n/a |
| Net Cash | 107.93M |
| Net Cash Per Share | $1.85 |
| Equity (Book Value) | 781,000 |
| Book Value Per Share | 0.01 |
| Working Capital | 107.93M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | 19.58M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | 19.58M |
| FCF Per Share | $0.34 |
Full Cash Flow Statement Margins
Gross margin is 7.43%, with operating and profit margins of 16.91% and -71.02%.
| Gross Margin | 7.43% |
| Operating Margin | 16.91% |
| Pretax Margin | -70.39% |
| Profit Margin | -71.02% |
| EBITDA Margin | n/a |
| EBIT Margin | 16.91% |
| FCF Margin | 41.66% |
Dividends & Yields
SPRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.53% |
| Shareholder Yield | -3.53% |
| Earnings Yield | -57.00% |
| FCF Yield | 37.70% |
Analyst Forecast
The average price target for SPRO is $5.33, which is 491.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.33 |
| Price Target Difference | 491.70% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |